欧林生物
(688319)
| 流通市值：26.23亿 | | | 总市值：36.96亿 |
| 流通股本：2.88亿 | | | 总股本：4.06亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 293,322,800.83 | 362,070,721.55 | 350,266,768.31 | 271,291,920.62 |
| 应收票据及应收账款 | 474,554,566.45 | 491,548,299.06 | 492,144,166.5 | 491,620,113.45 |
| 其中：应收票据 | 300,000 | 300,000 | - | 3,156,190 |
| 应收账款 | 474,254,566.45 | 491,248,299.06 | 492,144,166.5 | 488,463,923.45 |
| 预付款项 | 7,239,731.2 | 4,190,923.52 | 4,810,314.56 | 6,719,275.04 |
| 其他应收款合计 | 2,289,475.42 | 1,098,673.76 | 1,136,554.48 | 1,978,788.93 |
| 存货 | 76,670,451.68 | 72,116,155.57 | 76,776,556.91 | 85,066,649.13 |
| 其他流动资产 | 1,146,993.33 | 164,880.13 | 620,813.36 | 740,059.19 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 884,224,118.91 | 931,189,753.59 | 925,755,174.12 | 912,416,806.36 |
| 非流动资产: | | | | |
| 固定资产 | 234,442,271.24 | 239,280,608.31 | 235,519,783.24 | 236,342,895.84 |
| 在建工程 | 225,533,056.25 | 181,354,692.02 | 155,756,924.02 | 144,731,734.93 |
| 使用权资产 | 4,311,518.27 | 5,235,415.05 | 6,159,311.83 | 7,083,208.61 |
| 无形资产 | 16,573,728.78 | 16,820,970.47 | 17,092,044.82 | 17,333,082.88 |
| 开发支出 | 200,496,254.13 | 186,095,079.93 | 144,203,416.75 | 139,988,389.76 |
| 长期待摊费用 | 8,854,058.72 | 9,666,203.6 | 8,498,506.15 | 9,264,834.36 |
| 递延所得税资产 | 14,074,469.69 | 14,074,469.69 | 9,556,762.64 | 9,556,762.64 |
| 其他非流动资产 | 5,627,800 | 28,888,572.43 | 4,033,923 | 5,380,373 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 709,913,157.08 | 681,416,011.5 | 580,820,672.45 | 569,681,282.02 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,594,137,275.99 | 1,612,605,765.09 | 1,506,575,846.57 | 1,482,098,088.38 |
| 流动负债: | | | | |
| 短期借款 | 29,200,000 | 24,200,000 | 29,200,000 | 59,200,000 |
| 应付票据及应付账款 | 44,965,832.5 | 40,055,652.89 | 47,478,989.85 | 36,947,178.74 |
| 其中：应付票据 | - | - | 1,027,300.04 | 2,514,216.03 |
| 应付账款 | 44,965,832.5 | 40,055,652.89 | 46,451,689.81 | 34,432,962.71 |
| 合同负债 | 958,566.67 | 3,621,969.15 | 3,266,658.83 | 4,514,455.04 |
| 应付职工薪酬 | 405,599.3 | 13,807,913.41 | 426,663.58 | 388,071.35 |
| 应交税费 | 5,237,422.05 | 6,743,089.04 | 1,337,745.33 | 6,762,307.86 |
| 其他应付款合计 | 308,770,942.01 | 355,992,044.96 | 306,506,612.42 | 321,895,236.31 |
| 一年内到期的非流动负债 | 31,690,000 | 31,690,000 | 19,980,000 | 19,980,000 |
| 其他流动负债 | 28,757 | 108,659.07 | 97,999.76 | 135,433.65 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 421,257,119.53 | 476,219,328.52 | 408,294,669.77 | 449,822,682.95 |
| 非流动负债: | | | | |
| 长期借款 | 238,942,181.4 | 177,288,381.4 | 128,441,381.4 | 79,990,000 |
| 租赁负债 | 3,495,295.9 | 4,426,902.91 | 6,339,140.89 | 6,260,079.73 |
| 预计负债 | 92,264.67 | 1,212,625.54 | 236,938.61 | - |
| 递延收益 | 19,944,142.08 | 19,977,819.81 | 20,011,497.54 | 20,045,175.27 |
| 递延所得税负债 | 2,715,170.53 | 2,715,170.53 | 2,561,742.5 | 2,561,742.5 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 265,189,054.58 | 205,620,900.19 | 157,590,700.94 | 108,856,997.5 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 686,446,174.11 | 681,840,228.71 | 565,885,370.71 | 558,679,680.45 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 406,158,300 | 406,158,300 | 406,158,300 | 406,158,300 |
| 资本公积 | 609,967,790.65 | 605,746,395.33 | 600,732,481.87 | 589,836,618.9 |
| 减:库存股 | 7,961,870 | 7,961,870 | 7,961,870 | 7,961,870 |
| 盈余公积 | 8,615,917.45 | 8,615,917.45 | 2,657,753.78 | 2,657,753.78 |
| 未分配利润 | -121,650,121.3 | -95,653,191.14 | -76,966,829.39 | -78,704,518.18 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 895,130,016.8 | 916,905,551.64 | 924,619,836.26 | 911,986,284.5 |
| 少数股东权益 | 12,561,085.08 | 13,859,984.74 | 16,070,639.6 | 11,432,123.43 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 907,691,101.88 | 930,765,536.38 | 940,690,475.86 | 923,418,407.93 |
| 负债和股东权益合计 | 1,594,137,275.99 | 1,612,605,765.09 | 1,506,575,846.57 | 1,482,098,088.38 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-27 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |